Skip to Content
Søk Menu

Late-Breaking from ASH22 – Zanubrutinib has Now Proven Superiority to Ibrutinib

The ALPINE study is the first study to demonstrate a superior Progression-Free Survival (PFS) and safety profile of zanubrutinib compared to ibrutinib in patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL).

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

Emelie Hamotal Curovic Rotbain

Dansk Aften ASH 2024: Nye fremskridt i behandling af CLL

/ Emelie Hamotal Curovic Rotbain
ASH24CLL Play the Video 03:30
Ingrid Glimelius

High Infection Burden and Mortality in CLL Patients: A Call for Action

/ Ingrid Glimelius
ASH24CLL Play the Video 02:15
Paolo Ghia

Pirtobrutinib Outperforms Investigators’ Choice in Relapsed/Refractory CLL After BTK Inhibitor Therapy

/ Paolo Ghia
ASH24CLL Play the Video 03:54
Jennifer R Brown

Deep and Durable Response of Fixed-Duration Acalabrutinib in Combination with Venetoclax, +/- Obinutuzumab in Previously Untreated Adults with CLL

/ Jennifer R. Brown
ASH24CLL Play the Video 04:11
Florian Simon

Acalabrutinib Shows Promise for Elderly CLL Patients

/ Florian Simon
ASH24CLL Play the Video 05:20

CLL: Needs At Least 10 Years of Follow-Up for Clinical Trials

/ BestPractice Nordic
CLLEHA24
Paolo Ghia

Promising Efficacy of Zanubrutinib + Venetoclax Treatment in Patients with High-Risk Treatment-Naïve CLL/SLL with Del 17p and/or TP53 Mutation

/ Paolo Ghia
CLLEHA24 Play the Video 02:42
Alessandra Tedeschi

Impact of First-Year Dose Modifications of Acalabrutinib in Patients with CLL

/ Alessandra Tedeschi
CLLEHA24 Play the Video 01:52

Increased Relative Risk of Cancer for Relatives to Patients with Myelodysplastic Neoplasms and Leukemia

/ Nikolaj Juul Nitschke / Kirsten Grønbæk
KreftLeukemi
Back to top